Due to their own limitations in either potency or selectivity (e.g., compounds 8 h and 9e exhibit better anti-DOT1L activity but poor selectivity against MLL-rearranged leukemia cells than that of 3a and 3e), these compounds need further optimization. The gene discussed is KMT2A; the disease is leukemia.